Wet Age-Related Macular Degeneration
ANX007 for geographic atrophy receives priority medicine designation from EMA
The European Medicines Agency granted priority medicine designation to ANX007 for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Annexon Biosciences.
VIDEO: Sozinibercept shows good results in combination with VEGF-A inhibitors
SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Dante J. Pieramici, MD, overviews pharmacokinetics and safety data for sozinibercept.
What is your approach for treating GA with concomitant neovascular AMD?
The clinical trials have purposefully strict inclusion and exclusion criteria to control the variables that might affect the outcomes of an intervention.
EyePoint reports positive interim safety data for diabetic retinopathy, wet AMD treatment
EyePoint Pharmaceuticals has announced positive interim masked safety data for its investigational EYP-1901 for treatment of moderate to severe nonproliferative diabetic retinopathy and wet age-related macular degeneration.
FDA does not approve biologics license application for ONS-5010 for wet AMD treatment
The FDA issued a complete response letter noting its rejection of the biologics license application for ONS-5010 for the treatment of wet age-related macular degeneration, according to a press release from Outlook Therapeutics.
AMD highlights from ASRS: Positive real-world faricimab data, gene therapy and more
The American Society of Retina Specialists annual meeting featured study results and research in age-related macular degeneration.
Suprachoroidal axitinib for wet AMD safe in phase 1/2a trial
SEATTLE — Suprachoroidal axitinib had an “excellent” safety profile at all doses in the treatment of wet age-related macular degeneration, with early signs of durability and reduction in treatment burden, a speaker said here.
Phase 3 study meets primary efficacy endpoint for aflibercept biosimilar in wet AMD
An aflibercept biosimilar demonstrated positive results in the treatment of wet age-related macular degeneration in a phase 3 study, according to a press release from Sandoz.
PULSAR trial shows efficacy of aflibercept 8 mg in wet AMD with long treatment intervals
SEATTLE — The PULSAR trial in wet age-related macular degeneration demonstrated that aflibercept 8 mg administered every 12 or 16 weeks is noninferior in vision gains compared with aflibercept 2 mg every 8 weeks.
PULSAR: Extended dosing intervals for wet AMD maintained at 2 years with aflibercept 8 mg
The majority of patients with wet age-related macular degeneration who received aflibercept 8 mg maintained extended dosing intervals through 2 years in a pivotal trial, according to a press release from Regeneron.